Oesophagus / Esofago (C15.9) - Apoptotic frequencies are inversely related to levels of cell survival proteins in neoplastic development in patients with Barrett’s oesophagus
Keywords:
Barrett’s oesophagus, apoptosis, BCL-XL, NF-kBAbstract
Purpose: We aimed here to assess the apoptotic cell frequency in Barrett’s oesophagus tissue and the histological series leading to adenocarcinoma. In parallel, we also aimed to quantify the expression of several anti-apoptotic proteins. The purpose was to assess the role of these anti-apoptotic proteins in apoptosis resistance across this well defined neoplastic series. Methods: Apoptotic bodies were manually counted in 74 biopsy tissue sections after robust training (and the use of CD45 and caspase 3 as internal controls). Immunohistochemistry was used to measure the expression of BCL-XL, XIAP and BCL-2 in a subset of the same sections. Results: Apoptotic frequency dropped from 0.2% in the Barrett’s oesophagus and low grade dysplasia groups to <0.1% in the high grade dysplasia and adenocarcinoma groups. In parallel a marked increase in BCL-XL expression as the tissue progressed towards adenocarcinoma was observed. Moreover a non-significant increase in XIAP expression was detected. BCL-2 expression was low and did not change during the histological advancement. Conclusions: Anti-apoptotic protein expression increased across the histological series to cancer in Barrett’s oesophagus. This occurred in an inverse manner to the level of apoptotic cells. Apoptotic resistance may drive neoplastic development in the oesophagus and BCL-XL may be prime target for therapy.Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.